Novel antibody-based therapeutics have revolutionised healthcare and are a prominent feature on top-selling pharmaceutical lists. As antibody engineering and manufacturing technologies improve, previously untreatable diseases can be targeted with increased speed and efficiency. Creating a pathway that balances cost, speed and risk for therapeutic antibody development is crucial to successful and timely approval of new therapeutics.

Author: by Lonza

You may also be interested in:
Mammalian
Bispecific Antibody
Difficult to Express Proteins
Monoclonal Antibody
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center
vial filler
Webinar (on-demand)
Flexible-Dose Development Strategies for Today's Clinical Landscape
This on-demand webinar explores the importance of dose-flexible manufacturing strategies in modern...
Technical/Service brief
GMP Tissue Sourcing
A complex process, prone to misconceptions and pitfalls, to find the “right human tissue” that will...
UC-II
e-book
Authentically UC-II® e-book
Provides a understanding of the joint health market trends in India especially with the older...
Article
The Crucial Role of GS-CHO Innovation in Biopharmaceutical Progress
With a long standing track record of success, GS-CHO based expression systems have become the most...
Webinar (on-demand)
Extracellular vesicles - Setting-up the Path to IND with Advanced Characterization Packages
Abstract: During this webinar, our expert will share insights on how precise analytics and process...
Woman smiling
Webinar (on-demand)
Innovate with Lonza: Unlocking probiotic potential through category expansion and solving...
Ready to tap into the probiotic market? Lonza’s webinar promises a comprehensive exploration of the...
Technical/Service brief
End-To-End Production of T Cells on the Cocoon® Platform, Using Buoyancy-Activated Cell Sorting™ For...
Performance data of the Cocoon® Platform using Buoyancy-Activated Cell Sorting™ for T cell isolation...
AI-Enabled Route Scouting Service Scientists
Webinar (on-demand)
Innovative AI-Driven Solutions to Address the Growing Complexity of APIs
The complexity of small molecule active pharmaceutical ingredients (APIs) is rising, bringing longer...
Article
mRNA Research Services To Accelerate Your Project
Lonza Bend Early Phase
e-book
Navigating Commercial Drug Development Technologies for Formulation Excellence
Our Small Molecule division is focused on leveraging its technologies and expertise to address...
Monoclonal Antibody
Article
Understanding Glycosylation in Antibodies
Proteins often undergo a variety of post-translational modifications (PTMs) after their initial...
Article
Meet Your Lentiviral Vector Development and Supply Requirements with Xcite® Lenti, an Optimized...
Demand for lentiviral vectors (LVVs) as delivery vehicles for gene therapies is rising...